Karolinska Development AB (publ)
OM:KDEV Rapporto sulle azioni
Cap. di mercato: SEK 289.8m
Karolinska Development Salute del bilancio
Salute finanziaria criteri di controllo 6/6 Karolinska Development ha un patrimonio netto totale di SEK1.2B e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK1.2B e SEK13.4M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti SEK 49.72m Patrimonio netto SEK 1.23b Totale passività SEK 13.41m Totale attività SEK 1.24b
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV). Sep 23
New major risk - Revenue and earnings growth Sep 01
Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023) Sep 01 Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025
We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising Earnings May 04
First quarter 2024 earnings released Apr 28
Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election Apr 16
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Mar 25
New major risk - Revenue and earnings growth Mar 24
Chief Executive Officer recently bought kr81k worth of stock Feb 22
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Feb 18 Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024
Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022) Nov 19 Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Nov 09
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery Sep 21
Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022) Aug 27
Chief Legal Officer & Deputy CEO recently bought kr165k worth of stock Jun 22
Chief Legal Officer & Deputy CEO recently bought kr56k worth of stock May 08
Chief Legal Officer & Deputy CEO recently bought kr89k worth of stock Mar 29
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 28
Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021) Feb 19
Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data Feb 15
Chief Legal Officer & Deputy CEO recently bought kr84k worth of stock Dec 23
Third quarter 2022 earnings released Nov 19 Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023
Karolinska Development AB (publ), Annual General Meeting, May 16, 2023 Nov 18
Price target decreased to kr5.40 Nov 16
Less than half of directors are independent Nov 16
Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin Sep 28
Karolinska Development AB Announces Chief Financial Officer Changes Sep 07 Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria Sep 03
Second quarter 2022 earnings released Aug 20
Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047 Aug 20 Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023
Investor sentiment improved over the past week Jun 01
First quarter 2022 earnings released May 01
Price target increased to kr7.90 Apr 27
Less than half of directors are independent Apr 27
Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study Apr 26
Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020) Mar 29
Investor sentiment deteriorated over the past week Mar 07
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 28 Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Feb 08
Investor sentiment deteriorated over the past week Jan 14
Investor sentiment deteriorated over the past week Dec 15
Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others. Dec 14
Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin Dec 02
Third quarter 2021 earnings released Nov 19
Investor sentiment improved over the past week Nov 10
Investor sentiment improved over the past week Oct 26
Investor sentiment deteriorated over the past week Sep 10
Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020) Aug 21
Is Karolinska Development (STO:KDEV) Using Too Much Debt? Aug 19
Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program Aug 13
Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB. Jun 18
First quarter 2021 earnings released May 01
Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This Year Apr 27
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Mar 30
CFO & Deputy CEO Fredrik Jarrsten has left the company Mar 10 Karolinska Development AB Announces CFO Changes
Karolinska Development Appoints Johan Dighed as Deputy CEO Feb 27
New 90-day low: kr1.59 Feb 25
Karolinska Development AB (publ) Announces Management Appointments Feb 20
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Feb 13
New 90-day low: kr1.61 Feb 10
We're Not So Sure You Should Rely on Karolinska Development's (STO:KDEV) Statutory Earnings Feb 08
New 90-day low: kr1.80 Jan 21
Investor sentiment deteriorated over the past week Dec 28
New 90-day low: kr2.17 Dec 22
New 90-day low: kr2.31 Nov 16
New 90-day low: kr2.60 Oct 24
New 90-day low: kr2.61 Sep 18
Price target lowered to kr4.30 Sep 02
Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB. Jul 31
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( SEK63.2M ) di KDEV superano le sue passività a breve termine ( SEK13.4M ).
Passività a lungo termine: KDEV non ha passività a lungo termine.
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: KDEV è esente da debiti.
Riduzione del debito: KDEV non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 177.6%.
Analisi della pista di contanti Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.
Pista di liquidità stabile: KDEV ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero .
Previsione Cash Runway: KDEV ha una liquidità sufficiente per 2.1 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 2.1 % ogni anno.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
